Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for acute exacerbations of asthma and COPD
2018-004401-79Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of benralizumab in asthma and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by University of Oxford. Primary endpoint: VAS dyspnoea symptom score. Status: unknown.
02
Drugs
benralizumab
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2018-004401-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004401-79.